Heineken warns pubs GLP-1 weight-loss drugs may cut beer sales

Summarised from 2 outlets · Updated 23 Oct, 14:28 · Archive

Heineken has warned British pubs that weight-loss drugs such as Wegovy and Ozempic could reduce alcohol consumption.

Heineken has warned British pubs and bars that growing use of GLP-1 weight-loss drugs could lead to reduced beer and cider sales. The world's second-largest brewer sent a presentation to hospitality customers this month stating that medications such as Novo Nordisk's Ozempic and Wegovy suppress the desire to drink alcohol. This could result in 'fullness and fewer serves' of pints and make traditional multi-pint drinking sessions less frequent, the company cautioned.

The warning reflects a broader shift in consumer behaviour. About 10 million people in the United States took GLP-1 medications last year, according to JPMorgan research. Heineken identified trends among GLP-1 users including preference for smaller serves, lower alcohol drinks and premium products, though the company said in a statement that 'GLP-1 users are not simply replacing alcohol' but are 'becoming more purposeful in their choices'.

Heineken recommended that venues promote half-pints, low- and no-alcohol drinks, and pair drinks with small plates of food to offset potential declines in customer visits and spending. The company said it would 'continue to monitor how these behaviours evolve in 2027'. Heineken told Reuters the presentation was shared as part of regular engagement with UK hospitality businesses to help them understand how consumer habits are changing.

How it is being reported

• Heineken warns pubs to adapt as weight loss drugs shrink alcohol salesBeer generated nearly £14 billion of sales in British pubs, bars and restaurants in the year to February 2026The Independent · 23 Oct, 14:08
• Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubsWorld’s second largest brewer says use of drugs such as Wegovy can reduce desire to drink alcohol Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider. The world’s second largest brewer sent a presentation to British hospitality customers earlier this month warning that GLP-1 use – led by Ozempic and Wegovy – can reduce the desire to drink alcohol , which could lead to “fullness and fewer serves” of pints in pubs and bars. Continue reading...The Guardian · 23 Oct, 10:08

In this story: Heineken · Novo Nordisk · AB InBev · Ozempic · Wegovy

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem